Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy
| Autor: | Travis Rosen, Joshua C. Black, M. Soledad Cepeda, Richard C. Dart, Gabrielle E. Bau, Gregory P Wedin, Jody L. Green |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Washington
medicine.medical_specialty Risk Evaluation and Mitigation Opioid Analgesics ER/LA Oregon 03 medical and health sciences 0302 clinical medicine Original Research Articles Internal medicine Humans Medicine Prescription Drug Abuse REMS 030212 general & internal medicine Opioids & Substance Use Disorders Section Mortality Practice Patterns Physicians' Medical prescription 030505 public health business.industry Mortality rate Medical examiner General Medicine Opioid-Related Disorders Risk evaluation Anesthesiology and Pain Medicine Long acting Hydrocodone Opioid Delayed-Action Preparations Florida Neurology (clinical) 0305 other medical science business Opioid analgesics medicine.drug |
| Zdroj: | Pain Medicine: The Official Journal of the American Academy of Pain Medicine |
| ISSN: | 1526-4637 1526-2375 |
| DOI: | 10.1093/pm/pnz031 |
| Popis: | Objective To assess changes in mortality rates in extended-release and long-acting (ER/LA) opioid analgesics after the implementation of the Risk Evaluation and Mitigation Strategy (REMS). Setting All drug poisoning deaths in three states: Florida, Oregon, and Washington. Data were obtained through state vital records offices and the Researched Abuse, Diversion and Addiction-Related Surveillance System Medical Examiner Program. Methods Using cause-of-death literal text from death certificates, individual opioid active pharmaceutical ingredients (APIs) involved in each death were identified using rules-based natural language processing. Population-adjusted and prescriptions dispensed–adjusted mortality rates were calculated for all ER/LA opioid analgesic and individual opioid APIs. Rates before and after implementation of the REMS were compared. Rate changes were compared with rates from two APIs with little or no inclusion in the REMS: benzodiazepines and hydrocodone. Results The mean ER/LA opioid analgesic population-adjusted mortality rate significantly decreased in all three states (FL: P = 0.003; OR: P = 0.003; WA: P Conclusions The population-adjusted mortality rate of ER/LA opioid analgesics has decreased in three states. Notably, the contributions to mortality rates by individual opioid analgesics were not uniform across the three states in this study. However, these changes were not generally distinct from changes in mortality rates where comparator substances were involved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|